Palatin reports FY2024 net loss $29.7M, cash $9.5M; outlines clinical milestones for obesity, DED, ED, UC

PALATIN TECHNOLOGIES INC

2026-Q1 EPS reported -$19.71 vs consensus -$1.26 ▼ miss (-1469.5%)

Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.
Cash and cash equivalents $9.5M at June 30, 2024; auditor includes going concern explanatory paragraph.
Obesity Phase 2 MC4R+GLP-1 trial enrollment to complete early Q4 2024; topline results expected Q1 2025.
DED Phase 3 MELODY-2/3 trials to start enrollment Q1 2025; topline results anticipated Q4 2025.
Diabetic nephropathy Phase 2 BREAKOUT topline results expected Q4 2024; UC Phase 2 interim readout Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.